Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
International Journal of Clinical Oncology

Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum

Authors
Ryosuke Kawagoe
Toshikazu Moriwaki
Kentaro Yamazaki
Hiroki Yukami
Hiroyuki Uetake
Masahiro Tsuda
Takeshi Suto
Naotoshi Sugimoto
Hitoshi Ojima
Yasumasa Takii
Hisateru Yasui
Masato Komoda
Yasuhiro Shimada
Akihito Tsuji
Toshifumi Yamaguchi
Ryoichi Sawada
Katsunori Shinozaki
Satoshi Otsu
Kunitoshi Shigeyasu
Kenji Tsuchihashi
Takao Tamura
Manabu Shiozawa
Hideki Ueno
Tadamichi Denda
Takahiko Ito
Atsuo Takashima
Published in
International Journal of Clinical Oncology

Abstract

Background

For patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus doublet chemotherapy. However, the differences in outcomes between cetuximab and panitumumab remain unknown.

Methods

Clinical data of patients with left-sided all RAS or KRAS wild-type mCRC who received cetuximab or panitumumab plus doublet chemotherapy were retrospectively collected from 24 institutions in Japan. The patients were divided into two groups: the cetuximab and panitumumab groups. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were compared between the two groups.

Results

A total of 233 patients were enrolled: 87 (37.3%) in the cetuximab group and 146 (62.7%) in the panitumumab group. Median OS, PFS, and RR of the cetuximab and panitumumab groups were 26.6 months (95% confidence interval [CI], 19.7–33.4) versus 31.8 months (95% CI, 25.7–37.9), 9.7 months (95% CI, 6.9–12.5) versus 12.4 months (11.1–13.7), and 57.8% versus 71.0%, respectively. In multivariate analysis, OS and RR were significantly better in the panitumumab group than in the cetuximab group (adjusted hazard ratio 0.69, 95% CI 0.50–0.99, p = 0.04; adjusted odds ratio 2.00, 95% CI 1.07–3.73, p = 0.03) and PFS was similar between the two groups (adjusted hazard ratio 0.75, 95% CI 0.55–1.01, p = 0.05).

Conclusion

As a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.
Title
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Authors
Ryosuke Kawagoe
Toshikazu Moriwaki
Kentaro Yamazaki
Hiroki Yukami
Hiroyuki Uetake
Masahiro Tsuda
Takeshi Suto
Naotoshi Sugimoto
Hitoshi Ojima
Yasumasa Takii
Hisateru Yasui
Masato Komoda
Yasuhiro Shimada
Akihito Tsuji
Toshifumi Yamaguchi
Ryoichi Sawada
Katsunori Shinozaki
Satoshi Otsu
Kunitoshi Shigeyasu
Kenji Tsuchihashi
Takao Tamura
Manabu Shiozawa
Hideki Ueno
Tadamichi Denda
Takahiko Ito
Atsuo Takashima
Publication date
04-03-2026
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-026-02999-z
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

Case simulations: Biomarker-driven management of NSCLC (Link opens in a new window)

Do you want to assess your biomarker testing skills and management decisions? Use these simulation-based case studies based on realistic NSCLC scenarios to do so in a practical and secure environment.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
COMMISSIONED

How-to guide for healthcare professionals: understanding genomic reports

This educational activity was initiated, funded and co-developed by Boehringer Ingelheim and is intended for healthcare professionals in the UK and Ireland only. 

Genomic testing helps inform cancer diagnosis, prognosis, and treatment. A genomic report is generated by the laboratory carrying out next-generation sequencing to analyze biopsy samples. Access this educational microsite to learn more about typical genomic report content and how to interpret test results for patients with cancer.

NP-GB-106631 | Jan 2026

Commissioned by:
  • Boehringer Ingelheim
Learn more
Image Credits
Biomarker-driven management of NSCLC logo/© Springer Health+ IME, DNA double helix structure on a purple background/© 2025 Adobe